Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

We developed a metagenomic next-generation sequencing (mNGS) test using cell-free DNA
from body fluids to identify pathogens. The performance of mNGS testing of 182 body fluids …

The efficacy and potential limitations of molecular residual disease (MRD) detection urgently
need to be fully elucidated in a larger population of non–small cell lung cancer (NSCLC) …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Improving early cancer detection has the potential to substantially reduce cancer-related
mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing …

Molecular stratification can improve the management of advanced cancers, but requires
relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a …

Glioma‐derived cell‐free DNA (cfDNA) is challenging to detect using liquid biopsy because
quantities in body fluids are low. We determined the glioma‐derived DNA fraction in …

Early cancer detection aims to find tumors before they progress to an incurable stage. To
determine the potential of circulating tumor DNA (ctDNA) for cancer detection, we developed …